Connect Biopharma Holdings Limited (CNTB) annual cash flow statement — 7-year operating, investing & financing history
| Cash from Operations | -51.21M | -23.61M | -47.93M | -99.27M | -85.57M | -25.61M | -13.09M |
| Operating CF Margin % | -80009.38% | -90.7% | - | - | - | - | - |
| Operating CF Growth % | -116.86% | 50.74% | 51.72% | -16.01% | -234.15% | -95.56% | - |
| Net Income | -55.48M | -15.63M | -59.38M | -116.12M | -204.94M | -119.37M | -24.46M |
| Depreciation & Amortization | 704K | 660K | 988K | 1.01M | 640.98K | 221.05K | 114.61K |
| Stock-Based Compensation | 3.73M | 6.73M | 3.26M | 1.01M | 1.41M | 590.64K | 562.17K |
| Deferred Taxes | 0 | 0 | 0 | 3.37M | 106.37M | 89.68M | 8.3M |
| Other Non-Cash Items | -736K | 118K | -2.28M | -1.35M | 6.91K | 443.18K | 7.69K |
| Working Capital Changes | 580K | -15.49M | 9.48M | 7.16M | 3.27M | -436.29K | 2.38M |
| Change in Receivables | 776K | -789K | 1.04M | 3.37K | -2.53K | -1.43K | -439 |
| Change in Inventory | 0 | 0 | 0 | -3.37K | 2.53K | 1.43K | 439 |
| Change in Payables | 1.62M | -1.87M | -4.28M | 375.66K | 8.89M | 283.4K | 2.81M |
| Cash from Investing | 9.82M | -3.45M | 75.16M | -83.44M | -5.34M | 449.15K | -484.7K |
| Capital Expenditures | -434K | -750K | -294K | -4.28M | -7.46M | -2.34M | -155.52K |
| CapEx % of Revenue | 678.13% | 2.88% | - | - | - | - | - |
| Acquisitions | 0 | 0 | 2.94M | 79.16K | 47.73K | 53.46K | 329 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 775K | 123K | -84K | -79.16K | -47.74K | -53.46K | -329 |
| Cash from Financing | 1.09M | 227K | -246K | -91.28K | 206.66M | 140.74M | -57.45K |
| Debt Issued (Net) | 0 | 0 | -290K | -222K | -126K | -82.42K | -63.6K |
| Equity Issued (Net) | 1.09M | 227K | 44K | 18K | 221.47M | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -566K | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 119K | -19.12M | 140.83M | 7K |
| Net Change in Cash | -39.89M | -27.43M | 27M | -168.93M | 109.42M | 107.4M | -13.44M |
| Free Cash Flow | -51.64M | -24.36M | -48.22M | -103.55M | -93.03M | -27.95M | -13.25M |
| FCF Margin % | -80687.5% | -93.58% | - | - | - | - | - |
| FCF Growth % | -111.97% | 49.48% | 53.43% | -11.31% | -232.83% | -110.96% | - |
| FCF per Share | -0.93 | -0.44 | -0.88 | -1.88 | -1.78 | -0.52 | -0.24 |
| FCF Conversion (FCF/Net Income) | 0.92x | 1.51x | 0.77x | 0.84x | 0.42x | 0.21x | 0.54x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 292K | 111K | 120K | 462K | 0 | 0 | 0 |
Quick answers to the most common questions about buying CNTB stock.
Connect Biopharma Holdings Limited (CNTB) generated $-51.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Connect Biopharma Holdings Limited (CNTB) reported negative free cash flow of $51.6M in 2025, indicating capital requirements exceeded cash from operations.
Connect Biopharma Holdings Limited (CNTB) spent $0.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.